For the quarter ending 2025-09-30, ANVS had -$1,843,887 decrease in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss | -7,262,658 | -11,757,127 |
| Stock-based compensation expense | 444,647 | 996,505 |
| Change in fair value of warrants | -20,000 | -418,000 |
| Prepaid expenses and other current assets | -2,421,723 | 950,568 |
| Accounts payable | 1,137,715 | -1,331,663 |
| Accrued expenses | -209,042 | 255,800 |
| Net cash used in operating activities | -3,487,615 | -13,205,053 |
| Proceeds from issuance of common stock, net | 1,643,728 | 19,783,423 |
| Net cash provided by financing activities | 1,643,728 | 19,783,423 |
| Net increase in cash and cash equivalents | -1,843,887 | 6,578,370 |
| Cash and cash equivalents at beginning of period | 10,551,916 | - |
| Cash and cash equivalents at end of period | 15,286,399 | - |
Annovis Bio, Inc. (ANVS)
Annovis Bio, Inc. (ANVS)